Skip to main content
Log in

Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

In the past, our limited understanding of the processes involved in the initiation and growth of cancer hindered our ability to effectively treat most human malignancies and therapies were often associated with significant toxic side effects as well as re-emergence of disease. The development of drug delivery systems such as liposomes has improved the specificity of various conventional anticancer agents by enhancing drug accumulation in tumors while often decreasing exposure to susceptible healthy tissues. More recently, the identification of a wide range of genes and corresponding protein products that are altered in various human cancers has revealed new molecular targets for cancer therapy that may provide improved selectivity for tumor cells over traditional cytotoxic agents. This review discusses how advances in the sophistication of liposomal delivery systems may open new opportunities for combining novel molecular targeting strategies with pharmacological targeting via liposomes to optimize the therapy of many human malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lasic DD, Papahadjopoulos D: Science 267: 1275-1276, 1995

    PubMed  Google Scholar 

  2. Mastrangelo MJ, Berd D, Mathan FE, Lattime EC: Sem Oncol 23: 4-21, 1996

    Google Scholar 

  3. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR, Bally MB: Cancer Res 49: 5922-5930, 1989

    PubMed  Google Scholar 

  4. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z: Cancer Res 42: 4734-4739, 1982

    PubMed  Google Scholar 

  5. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D: Cancer Res 52: 6774-6781, 1992

    PubMed  Google Scholar 

  6. Mayer LD, Dougherty G, Harasym TO, Bally MB: J Pharmacol Exp Therapeut 280: 1406-1414, 1997

    Google Scholar 

  7. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK: Cancer Res 54: 3352-3356, 1994

    PubMed  Google Scholar 

  8. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD: Br J Cancer 72: 896-904, 1995

    PubMed  Google Scholar 

  9. Subramanian D, Muller MT: Oncol Res 7: 461-469, 1995

    PubMed  Google Scholar 

  10. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D: Cancer Res 54: 2186-2191, 1994

    PubMed  Google Scholar 

  11. Holland JW, Hui C, Cullis PR, Madden TD: Biochemistry 35: 2618-2624, 1996

    Article  PubMed  Google Scholar 

  12. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S: FEBS Lett 388: 115-118, 1996

    Article  PubMed  Google Scholar 

  13. Ahmad I, Longenecker M, Samuel J, Allen TM: Cancer Res 53: 1484-1488, 1993

    PubMed  Google Scholar 

  14. Marjan J, Charrios G, Lopes de Menezes D, Allen TM: Proc Amer Assoc Cancer Res 37: A2103, 1996

    Google Scholar 

  15. Lee RJ, Low PS: J Biol Chem 269: 3198-3204, 1994

    PubMed  Google Scholar 

  16. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC: Adv Pharmacol 40: 400-435, 1997

    Google Scholar 

  17. Mizuguchi H, Nakanishi M, Nakanishi T, Nakagawa T, Nakagawa S, Mayumi T: Br J Cancer 73: 472-476, 1996

    PubMed  Google Scholar 

  18. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y: Br J Cancer 76: 83-89, 1997

    PubMed  Google Scholar 

  19. Gibbs JB, Oliff A: Ann Rev Pharmacol Toxicol 37: 143-166, 1997

    Article  Google Scholar 

  20. Prins I, de Vries EGF, Mulder NH: Clin Oncol 5: 245-252, 1994

    Google Scholar 

  21. Hynes NE, Stern DF: Biochim Biophys Acta 1198: 165-184, 1994

    PubMed  Google Scholar 

  22. Kartner N, Riorden JR, Ling V: Science 221: 1285-1288, 1983

    PubMed  Google Scholar 

  23. Hickman JA: Eur J Cancer 32A: 921-926, 1996

    Article  PubMed  Google Scholar 

  24. Fan D, Beltran PJ, O'Brian CA: In: Kellen JA (ed) Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton pp. 93-125, 1994

    Google Scholar 

  25. Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zuechetti M, D'Incalci M: Cancer Chemother Pharmacol 36: 335-340, 1995

    PubMed  Google Scholar 

  26. Weeb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Lancet 349: 1137-1141, 1997

    Article  PubMed  Google Scholar 

  27. Cotter F, Hohnson P, Hall P, Pocock C, Al Mahdi N, Cowell J, Morgan G: Oncogene 9: 3049-3055, 1994

    PubMed  Google Scholar 

  28. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielson M. Proc Natl Acad Sci USA 84: 7413-7417, 1987

    PubMed  Google Scholar 

  29. Hofland H, Huang L: Biochem Biophys Res Commun 207: 492-496, 1995

    Article  PubMed  Google Scholar 

  30. Li S, Huang L: Gene Therapy 4: 891-900, 1997

    Article  PubMed  Google Scholar 

  31. Hong K, Zheng W, Baker A, Papahadjopoulos D: FEBS Lett 400: 233-237, 1997

    Article  PubMed  Google Scholar 

  32. Krishna R, Mayer LD: Cancer Res 57: 5246-5253, 1997

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayer, L.D. Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies. Cancer Metastasis Rev 17, 211–218 (1998). https://doi.org/10.1023/A:1006070906949

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006070906949

Navigation